Cancer-Targeting Compound 1 is used in the research of hormone-​related cancer, extracted from patent WO 2008021331 A2. In Vitro: Cancer-Targeting Compound 1 is useful for the research of hormone-related conditions including contraception, treating or preventing fibroids, endometriosis, dysfunctional bleeding, uterine leiomyomata, polycystic ovary syndrome, or hormone-dependent carcinomas, providing hormone replacement therapy, stimulating food intake or synchronizing estrus^[1].